anita j chawla  analysis group menu experts  staff anita j chawla managing principal expert menlo park  email download vcard summary selected publishing news education phd economics university of michigan ba economics and political science wellesley college summary of experience dr chawla has more than  years of experience as an economist in the health care sector since joining analysis group in  she has helped global biopharmaceutical diagnostic and medical device manufacturers  as well as developmentstage companies  address product development and commercialization objectives particularly as they relate to market access her work has spanned a wide range of therapeutic areas including multiple indications in oncology her recent client work includes landscape assessments economic modeling and strategic plans to inform evidence generation in the context of product development and market access launch strategy forecasts to help prioritize research and support licensing and venture funding discussions payer research and advisory boards and launch materials that communicate a products clinical and economic value to support evidencebased reviews dr chawla recently led an engagement comprising a fully integrated market access strategy and related tactics to support the launch of a novel drug to treat an orphan disease dr chawlas recent publications include an assessment of the impact of regulatory requirements for cardiovascular risk evaluation for diabetes therapies she has served as a reviewer or referee for several journals including value in health health affairs health services research journal of the american medical association and journal of business and economic statistics prior to joining analysis group she was head of the health economics and outcomes research department at genentech inc where she also supported the oncology franchise read anitas profile selected publishing following recent trends in affordable care act insurance law september   chawla a cook k health care insurance estimating the incremental net health beneﬁt of requirements for cardiovascular risk evaluation for diabetes therapies pharmacoepidemiology and drug safety january  chawla a mytelka d mcbride s nellesen d elkins b ball d kalsekar a towse a garrison l health care strategy policy  analytics comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation a review of the literature from the past decade postgraduate medicine march  vol  no  nellesen d chawla a oh dl weissman t lavins bj murray cw health care a systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation journal of managed care pharmacy novemberdecember  vol  no  nellesen d yee k chawla a lewis be carson rt health care personalized medicine trends in clinical studies based on national registry data ispor poster  nellesen d person a yee k chawla a health care news september   analysis group experts publish article examining recent trends in affordable care act insurance health care insurance january   new study examining care pathways finds need for improving transparency establishing best practices health care october   bloomberg bna publication cites managing principal anita chawla on business strategy in personalized medicine health care strategy policy  analytics august   analysis group health care consultants present at pharmacoepidemiology and drug safety conference epidemiology  biostatistics health care july   special issue of pharmacoeconomics journal on economic consequences of obesity edited by analysis group health care september   managing principal anita chawla discusses the commercialization of personalized medicine health care march   health care consultants assess impact of fda policy intervention for evaluating cardiovascular risk in new diabetes drugs health care strategy policy  analytics expertisehealth care strategy policy  analytics health care bulletin recent trends in affordable care act insurance ag feature antiobesity drug development risks and expectations health care bulletin enhancing product value propositions in the pipeline video the economic consequences of obesity prev next our  privacy policy and terms of use on our website have changed additionally this website uses cookies to analyze traffic and help us improve the user experience of the site please review our privacy policy and terms regarding cookies for additional information by continuing to use this site you agree to the privacy policy and terms of use including the use of cookies close anita j chawla  analysis group menu experts  staff anita j chawla managing principal expert menlo park  email download vcard summary selected publishing news education phd economics university of michigan ba economics and political science wellesley college summary of experience dr chawla has more than  years of experience as an economist in the health care sector since joining analysis group in  she has helped global biopharmaceutical diagnostic and medical device manufacturers  as well as developmentstage companies  address product development and commercialization objectives particularly as they relate to market access her work has spanned a wide range of therapeutic areas including multiple indications in oncology her recent client work includes landscape assessments economic modeling and strategic plans to inform evidence generation in the context of product development and market access launch strategy forecasts to help prioritize research and support licensing and venture funding discussions payer research and advisory boards and launch materials that communicate a products clinical and economic value to support evidencebased reviews dr chawla recently led an engagement comprising a fully integrated market access strategy and related tactics to support the launch of a novel drug to treat an orphan disease dr chawlas recent publications include an assessment of the impact of regulatory requirements for cardiovascular risk evaluation for diabetes therapies she has served as a reviewer or referee for several journals including value in health health affairs health services research journal of the american medical association and journal of business and economic statistics prior to joining analysis group she was head of the health economics and outcomes research department at genentech inc where she also supported the oncology franchise read anitas profile selected publishing following recent trends in affordable care act insurance law september   chawla a cook k health care insurance estimating the incremental net health beneﬁt of requirements for cardiovascular risk evaluation for diabetes therapies pharmacoepidemiology and drug safety january  chawla a mytelka d mcbride s nellesen d elkins b ball d kalsekar a towse a garrison l health care strategy policy  analytics comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation a review of the literature from the past decade postgraduate medicine march  vol  no  nellesen d chawla a oh dl weissman t lavins bj murray cw health care a systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation journal of managed care pharmacy novemberdecember  vol  no  nellesen d yee k chawla a lewis be carson rt health care personalized medicine trends in clinical studies based on national registry data ispor poster  nellesen d person a yee k chawla a health care news september   analysis group experts publish article examining recent trends in affordable care act insurance health care insurance january   new study examining care pathways finds need for improving transparency establishing best practices health care october   bloomberg bna publication cites managing principal anita chawla on business strategy in personalized medicine health care strategy policy  analytics august   analysis group health care consultants present at pharmacoepidemiology and drug safety conference epidemiology  biostatistics health care july   special issue of pharmacoeconomics journal on economic consequences of obesity edited by analysis group health care september   managing principal anita chawla discusses the commercialization of personalized medicine health care march   health care consultants assess impact of fda policy intervention for evaluating cardiovascular risk in new diabetes drugs health care strategy policy  analytics expertisehealth care strategy policy  analytics health care bulletin recent trends in affordable care act insurance ag feature antiobesity drug development risks and expectations health care bulletin enhancing product value propositions in the pipeline video the economic consequences of obesity prev next our  privacy policy and terms of use on our website have changed additionally this website uses cookies to analyze traffic and help us improve the user experience of the site please review our privacy policy and terms regarding cookies for additional information by continuing to use this site you agree to the privacy policy and terms of use including the use of cookies close dr anita j chawla joins cytrx board of directors to add additional drug commercialization dr anita j chawla joins cytrx board of directors to add additional drug commercialization expertise in oncology mar    et from cytrx corporation los angeles march   prnewswire  cytrx corporation nasdaq cytr a biopharmaceutical research and development company specializing in oncology today announced the appointment of anita j chawla phd to its board of directors dr chawla brings over  years of experience as an economist in the health care industry to cytrx with a proven track record helping pharmaceutical biotechnology medical device and diagnostic companies achieve their product development and commercialization objectives  most recently she has provided strategic consultancy services to a variety of life science companies including cytrx  with broad experience advising companies in matters including corporate and business unit strategy market dynamics across multiple therapeutic areas reimbursement health economics and business analytics her appointment strengthens the executive leadership team and adds significant operational and commercial expertise we are delighted to welcome anita to the cytrx board of directors said steven a kriegsman chairman and ceo of cytrx  anita is a talented health economist who has become a very successful and trusted advisor to biopharmaceutical companies  she has been intimately involved in providing strategic guidance for product development and commercialization in oncology for many successful biopharmaceutical companies and we believe her contributions will be invaluable as we prepare to commercialize aldoxorubicin and other new treatments for cancer patients cytrxs aldoxorubicin is a novel targeted therapeutic that has shown promise in various oncology clinical trials and has significant potential in several cancer types said dr chawla i look forward to working alongside the board and management team to help cytrx navigate the clinical and commercial development of its lead asset and create long term value for shareholders dr chawla currently serves as managing principal at analysis group a consultancy firm that provides economic financial and business strategy consulting to corporations law firms and government agencies  clients include major pharmaceutical manufacturers biotech and medical device companies including smaller innovative companies  prior to joining analysis group she held positions at genentech inc as the head of the health economics  outcomes research department where she also supported the oncology franchise the medstat group now truven health analytics and the american medical association center for health policy research  she has over  professional presentations technical reports and publications to her credit  dr chawla also serves on the board of trustees of newbury college in brookline massachusetts  she has served as a reviewer or referee for several journals including value in health health affairs health services research journal of the american medical association and journal of business and economic statistics  dr chawla holds a phd in economics from the university of michigan and received a bachelor of arts degree in economics and political science from wellesley college dr anita chawla bears no familial relation to sant p chawla md fracp director of the sarcoma oncology center and principal investigator of the companys global phase  clinical trial in soft tissue sarcoma or shanta chawla md vice president clinical development at cytrx about cytrx corporation cytrx corporation is a biopharmaceutical research and development company specializing in oncology  cytrx currently is focused on the clinical development of aldoxorubicin formerly known as inno its improved version of the widely used chemotherapeutic agent doxorubicin cytrx has initiated under a special protocol assessment a pivotal phase  global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy and recently announced that it has received approval from the fda to continue dosing patients with aldoxorubicin until disease progression in that clinical trial cytrx is currently evaluating aldoxorubicin in a global phase b clinical trial in small cell lung cancer a phase  clinical trial in hivrelated kaposis sarcoma a phase  clinical trial in patients with latestage glioblastoma brain cancer a phase b trial in combination with ifosfamide in patients with soft tissue sarcoma and a phase b trial in combination with gemcitabine in subjects with metastatic solid tumors cytrx has completed a global phase b clinical trial with aldoxorubicin as a firstline therapy for soft tissue sarcomas a phase b clinical trial primarily in the same indication a phase b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a phase b pharmacokinetics clinical trial in patients with metastatic solid tumors cytrx plans to expand its pipeline of oncology candidates at its laboratory facilities in freiburg germany based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites  for more information about cytrx corporation visit wwwcytrxcom   forwardlooking statements this press release contains forwardlooking statements within the meaning of section e of the securities exchange act of  as amended such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forwardlooking statements including risks relating to the outcome timing and results of cytrxs clinical trials the timing or fda approval of projected commercial sales of aldoxorubicin the risk that any future human testing of aldoxorubicin might not produce results similar to those seen in past human or animal testing risks related to cytrxs ability to manufacture its drug candidates in a timely fashion costeffectively or in commercial quantities in compliance with stringent regulatory requirements risks related to cytrxs need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts including the phase  clinical development of aldoxorubicin risks related to lawsuits that have been brought against the company and its officers andor directors for alleged violations of the securities laws and the risks and uncertainties described in the most recent annual and quarterly reports filed by cytrx with the securities and exchange commission and current reports filed since the date of cytrxs most recent annual report all forwardlooking statements are based upon information available to cytrx on the date the statements are first published cytrx undertakes no obligation to publicly update or revise any forwardlooking statements whether as a result of new information future events or otherwise investor relations argot partners michelle carroll  michelleargotpartnerscom media argot partners eliza schleifstein  elizaargotpartnerscom company contact cytrx corporation david j haen vice president business development and investor relations  x dhaencytrxcom    source cytrx corporation related links httpwwwcytrxcom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more apr    et preview cytrx announces publication of glioblastoma clinical case study in journal of nuclear medicine  radiation therapy mar    et preview cytrx reports  financial results my news release contains wide tables view fullscreen read more may    et cytrx announces reshaping of clinical and regulatory executive may    et cytrx announces update on the regulatory pathway for may    et cytrx to present global phase  aldoxorubicin clinical data in looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search angenus xmlnsfbhttpogpmensfb xmlnsaddthishttpwwwaddthiscomhelpapispec prefixog httpogpmens dr anita j chawla joins cytrx board of directors  centerwatch news online home » news » awards  advancement » dr anita j chawla joins cytrx board of directors dr anita j chawla joins cytrx board of directors thursday march   cytrx a biopharmaceutical rd company specializing in oncology has appointed anita j chawla phd to its board of directors chawla brings over  years of experience as an economist in the health care industry to cytrx with a proven track record helping pharmaceutical biotechnology medical device and diagnostic companies achieve their product development and commercialization objectives previously she has provided strategic consultancy services to a variety of life science companies including cytrx with broad experience advising companies in matters including corporate and business unit strategy market dynamics across multiple therapeutic areas reimbursement health economics and business analytics her appointment strengthens the executive leadership team and adds significant operational and commercial expertise “cytrx’s aldoxorubicin is a novel targeted therapeutic that has shown promise in various oncology clinical trials and has significant potential in several cancer types” said chawla “i look forward to working alongside the board and management team to help cytrx navigate the clinical and commercial development of its lead asset and create long term value for shareholders” chawla currently is managing principal at analysis group a consultancy firm that provides economic financial and business strategy consulting to corporations law firms and government agencies clients include major pharmaceutical manufacturers biotech and medical device companies including smaller innovative companies prior to joining analysis group she held positions at genentech as the head of the health economics  outcomes research department where she also supported the oncology franchise the medstat group now truven health analytics and the american medical association center for health policy research related posts proteus and otsuka to develop novel digital health products creating your personal secret sauce for site success top stories for the week of august th  tactics for recruiting diverse patient populations ipsen harvard medical school to collaborate guest commentary key imaging technology—dcemri july  ﻿partnership unveils ehredc integration mayo clinic and nference form qrativ ai platform for developing rare disease therapies already a subscriber log in to your digital subscription subscribe to cwweekly july revisiting patient diversity in clinical trials… again representative patient populations essential to new drug development preparing sites for acquisition buyers attracted to site growth unique assets and strategy   june electronic health records gain ground in clinical research ehr platforms play growing role in integrating clinical research and clinical care assessing the strategic impact of supply chain management rising importance in supporting investigative site and patient engagement   already a subscriber log in to your digital subscription purchase a single issue subscribe to the centerwatch monthly twitter news centerwatch twitter news centerwatch copyright   centerwatch contact us privacy glossary site map ﻿ bpm summit  anita j chawla phd about homeaboutadvisory boardanita j chawla phd anita j chawla phd rss managing principal analysis group dr chawla has worked as a health economist for over  years she has extensive experience using economic analyses to support the business objectives of life sciences companies in her work dr chawla has assessed the value of therapies to inform health care decision makers since joining analysis group in  she has specialized in market access and commercial strategy supported by health care analytics including both retrospective analyses and economic modeling to assess potential future market outcomes with her industry experience and training as an economist dr chawla has helped clients address business challenges associated with product development and commercialization particularly those related to requirements for coverage and reimbursement she has led multiple engagements to assist life sciences clients in preparing for evidencebased review in a wide range of therapeutic areas recent engagements have included value proposition evidence strategy and evidence development to support product launches and ongoing demonstration of value and forecasting and modeling to support market planning and valuation dr chawla’s recent publications include an assessment of manufacturers’ investment decisions in weight management drug development she has served as a reviewer or referee for several journals including health affairs health services research the journal of the american medical association the journal of managed care pharmacy and value in health prior to joining analysis group dr chawla was head of the health economics and outcomes research department at genentech page not found  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street page not found sorry the page youre looking for is not available you might want to try our homepage our most popular stories  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers anita j chawla phd executive profile  biography  bloomberg july    am et professional services company overview of analysis group inc snapshotpeople  overviewboard memberscommittees executive profile anita j chawla phdmanaging principal analysis group incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industries background dr anita j chawla phd has been a managing principal of analysis group inc since october  dr chawla has more than  years experience as a health economist she has extensive experience using economic analyses to support the business objectives of life sciences companies as a member of analysis groups menlo park office dr chawla has played a lead role in developing an early phase economicmodeling capability for pharmaceuticalsan approach that connects  strategic planning with health economics she has assessed the value of a wide range of therapies to inform health care decision makers such as physicians patients payers and policy makers an expert in all phases of drug development she has designed economic and outcomes research strategies for product development and commercialization objectives dr chawla has conducted research and published on a range of health economics issues including treatment patterns and outcomes economic burden of various illnesses costeffectiveness analysis in clinical trials drug spending trends and performance measures for prescription drug management she served as an independent director of cytrx corporation since march   until july   she is a member of the american economic association the american society of health economists and the international society for pharmacoeconomics and outcomes research she has served as a reviewer or referee for several journals including health affairs journal of the american medical association and journal of business and economic statistics prior to joining analysis group dr chawla served as the director of health economics and outcomes research at genentech inc she received her phd in economics from the university of michigan and her ba in economics and political science from wellesley collegeread full background corporate headquarters  huntington avenueboston massachusetts united statesphone fax  board members memberships there is no board members memberships data available education phd university of michiganba wellesley college other affiliations cytrx corporationuniversity of michiganwellesley college annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact analysis group inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close company update nasdaqcytr dr anita j chawla joins cytrx board of directors to add additional drug commercialization expertise in oncology  smarter analyst  login  connect premium services company update nasdaqcytr dr anita j chawla joins cytrx board of directors to add additional drug commercialization expertise in oncology corey williamsmarch    am edt share on cytrx corporation nasdaqcytr a biopharmaceutical research and development company specializing in oncology announced the appointment of anita j chawla phd to its board of directors dr chawla brings over  years of experience as an economist in the health care industry to cytrx with a proven track record helping pharmaceutical biotechnology medical device and diagnostic companies achieve their product development and commercialization objectives  most recently she has provided strategic consultancy services to a variety of life science companies including cytrx  with broad experience advising companies in matters including corporate and business unit strategy market dynamics across multiple therapeutic areas reimbursement health economics and business analytics her appointment strengthens the executive leadership team and adds significant operational and commercial expertise “we are delighted to welcome anita to the cytrx board of directors” said steven a kriegsman chairman and ceo of cytrx  “anita is a talented health economist who has become a very successful and trusted advisor to biopharmaceutical companies  she has been intimately involved in providing strategic guidance for product development and commercialization in oncology for many successful biopharmaceutical companies and we believe her contributions will be invaluable as we prepare to commercialize aldoxorubicin and other new treatments for cancer patients” “cytrx’s aldoxorubicin is a novel targeted therapeutic that has shown promise in various oncology clinical trials and has significant potential in several cancer types” said dr chawla “i look forward to working alongside the board and management team to help cytrx navigate the clinical and commercial development of its lead asset and create long term value for shareholders” dr chawla currently serves as managing principal at analysis group a consultancy firm that provides economic financial and business strategy consulting to corporations law firms and government agencies  clients include major pharmaceutical manufacturers biotech and medical device companies including smaller innovative companies  prior to joining analysis group she held positions at genentech inc as the head of the health economics  outcomes research department where she also supported the oncology franchise the medstat group now truven health analytics and the american medical association center for health policy research  she has over  professional presentations technical reports and publications to her credit  dr chawla also serves on the board of trustees of newbury college in brookline massachusetts  she has served as a reviewer or referee for several journals including value in health health affairshealth services research journal of the american medical association and journal of business and economic statistics  dr chawla holds a phd in economics from the university of michigan and received a bachelor of arts degree in economics and political science from wellesley college dr anita chawla bears no familial relation to sant p chawla md fracp director of the sarcoma oncology center and principal investigator of the company’s global phase  clinical trial in soft tissue sarcoma or shanta chawla md vice president clinical development at cytrx shares of cytrx closed yesterday at   cytr has a year high of  and a year low of  the stock’s day moving average is  and it’s day moving average is  on the ratings front cytrx has been the subject of a number of recent research reports in a report issued on january  aegis capital corp analyst yi chen maintained a buy rating on cytr with a price target of  which represents a potential upside of  from where the stock is currently trading according to tipranks chen has a total average return of  a  success rate and is ranked  out of  analysts cytrx corp is a biopharmaceutical research and development company specializing in oncology its oncology pipeline includes three clinicalstage drug candidates in various stages of development aldoxorubicin tamibarotene and bafetinib cytrcytrx you may also like see what other wall street analystsfinancial bloggers say about cytr which stocks are top  analysts buying find out here see what corporate insiders are buying find morerelated articles sabby capital’s hal mintz flips cytrx corporation cytr initiates mannkind corporation mnkd harriet lefton june   contributor opinionsexclusivehealthcare jefferies slashes price target for cytrx corporation cytr following disappointing phase  trial julie lamb editor july   healthcareinsights fbr slashes price target on cytrx corporation cytr following clinical trial setback peter murray editor july   healthcareinsights stay ahead of everyone else get the latest stock news alerts thank you for signing up error signing up please try again sign me up dr anita j chawla joins cytrx board of directors to add additional drug commercialization expertise in oncology  the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases dr anita j chawla joins cytrx board of directors to add additional drug commercialization expertise in oncology mar   am edt los angeles march   prnewswire  cytrx corporation nasdaq cytr a biopharmaceutical research and development company specializing in oncology today announced the appointment of anita j chawla phd to its board of directors dr chawla brings over  years of experience as an economist in the health care industry to cytrx with a proven track record helping pharmaceutical biotechnology medical device and diagnostic companies achieve their product development and commercialization objectives  most recently she has provided strategic consultancy services to a variety of life science companies including cytrx  with broad experience advising companies in matters including corporate and business unit strategy market dynamics across multiple therapeutic areas reimbursement health economics and business analytics her appointment strengthens the executive leadership team and adds significant operational and commercial expertise we are delighted to welcome anita to the cytrx board of directors said steven a kriegsman chairman and ceo of cytrx  anita is a talented health economist who has become a very successful and trusted advisor to biopharmaceutical companies  she has been intimately involved in providing strategic guidance for product development and commercialization in oncology for many successful biopharmaceutical companies and we believe her contributions will be invaluable as we prepare to commercialize aldoxorubicin and other new treatments for cancer patients cytrxs aldoxorubicin is a novel targeted therapeutic that has shown promise in various oncology clinical trials and has significant potential in several cancer types said dr chawla i look forward to working alongside the board and management team to help cytrx navigate the clinical and commercial development of its lead asset and create long term value for shareholders dr chawla currently serves as managing principal at analysis group a consultancy firm that provides economic financial and business strategy consulting to corporations law firms and government agencies  clients include major pharmaceutical manufacturers biotech and medical device companies including smaller innovative companies  prior to joining analysis group she held positions at genentech inc as the head of the health economics  outcomes research department where she also supported the oncology franchise the medstat group now truven health analytics and the american medical association center for health policy research  she has over  professional presentations technical reports and publications to her credit  dr chawla also serves on the board of trustees of newbury college in brookline massachusetts  she has served as a reviewer or referee for several journals including value in health health affairs health services research journal of the american medical association and journal of business and economic statistics  dr chawla holds a phd in economics from the university of michigan and received a bachelor of arts degree in economics and political science from wellesley college dr anita chawla bears no familial relation to sant p chawla md fracp director of the sarcoma oncology center and principal investigator of the companys global phase  clinical trial in soft tissue sarcoma or shanta chawla md vice president clinical development at cytrx about cytrx corporation cytrx corporation is a biopharmaceutical research and development company specializing in oncology  cytrx currently is focused on the clinical development of aldoxorubicin formerly known as inno its improved version of the widely used chemotherapeutic agent doxorubicin cytrx has initiated under a special protocol assessment a pivotal phase  global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy and recently announced that it has received approval from the fda to continue dosing patients with aldoxorubicin until disease progression in that clinical trial cytrx is currently evaluating aldoxorubicin in a global phase b clinical trial in small cell lung cancer a phase  clinical trial in hivrelated kaposis sarcoma a phase  clinical trial in patients with latestage glioblastoma brain cancer a phase b trial in combination with ifosfamide in patients with soft tissue sarcoma and a phase b trial in combination with gemcitabine in subjects with metastatic solid tumors cytrx has completed a global phase b clinical trial with aldoxorubicin as a firstline therapy for soft tissue sarcomas a phase b clinical trial primarily in the same indication a phase b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a phase b pharmacokinetics clinical trial in patients with metastatic solid tumors cytrx plans to expand its pipeline of oncology candidates at its laboratory facilities in freiburg germany based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites  for more information about cytrx corporation visit wwwcytrxcom   forwardlooking statements this press release contains forwardlooking statements within the meaning of section e of the securities exchange act of  as amended such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forwardlooking statements including risks relating to the outcome timing and results of cytrxs clinical trials the timing or fda approval of projected commercial sales of aldoxorubicin the risk that any future human testing of aldoxorubicin might not produce results similar to those seen in past human or animal testing risks related to cytrxs ability to manufacture its drug candidates in a timely fashion costeffectively or in commercial quantities in compliance with stringent regulatory requirements risks related to cytrxs need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts including the phase  clinical development of aldoxorubicin risks related to lawsuits that have been brought against the company and its officers andor directors for alleged violations of the securities laws and the risks and uncertainties described in the most recent annual and quarterly reports filed by cytrx with the securities and exchange commission and current reports filed since the date of cytrxs most recent annual report all forwardlooking statements are based upon information available to cytrx on the date the statements are first published cytrx undertakes no obligation to publicly update or revise any forwardlooking statements whether as a result of new information future events or otherwise investor relations argot partners michelle carroll  michelleargotpartnerscom media argot partners eliza schleifstein  elizaargotpartnerscom company contact cytrx corporation david j haen vice president business development and investor relations  x dhaencytrxcom    to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesdranitajchawlajoinscytrxboardofdirectorstoaddadditionaldrugcommercializationexpertiseinoncologyhtml source cytrx corporation the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more dr anita j chawla joins cytrx corporation board of directors to add additional drug commercialization expertise in oncology employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       dr anita j chawla joins cytrx corporation cytr board of directors to add additional drug commercialization expertise in oncology tweet   am los angeles march   prnewswire  cytrx corporation nasdaq cytr a biopharmaceutical research and development company specializing in oncology today announced the appointment of anita j chawla phd to its board of directorsdr chawla brings over  years of experience as an economist in the health care industry to cytrx with a proven track record helping pharmaceutical biotechnology medical device and diagnostic companies achieve their product development and commercialization objectives  most recently she has provided strategic consultancy services to a variety of life science companies including cytrx  with broad experience advising companies in matters including corporate and business unit strategy market dynamics across multiple therapeutic areas reimbursement health economics and business analytics her appointment strengthens the executive leadership team and adds significant operational and commercial expertisewe are delighted to welcome anita to the cytrx board of directors said steven a kriegsman chairman and ceo of cytrx  anita is a talented health economist who has become a very successful and trusted advisor to biopharmaceutical companies  she has been intimately involved in providing strategic guidance for product development and commercialization in oncology for many successful biopharmaceutical companies and we believe her contributions will be invaluable as we prepare to commercialize aldoxorubicin and other new treatments for cancer patientscytrxs aldoxorubicin is a novel targeted therapeutic that has shown promise in various oncology clinical trials and has significant potential in several cancer types said dr chawla i look forward to working alongside the board and management team to help cytrx navigate the clinical and commercial development of its lead asset and create long term value for shareholdersdr chawla currently serves as managing principal at analysis group a consultancy firm that provides economic financial and business strategy consulting to corporations law firms and government agencies  clients include major pharmaceutical manufacturers biotech and medical device companies including smaller innovative companies  prior to joining analysis group she held positions at genentech inc as the head of the health economics  outcomes research department where she also supported the oncology franchise the medstat group now truven health analytics and the american medical association center for health policy research  she has over  professional presentations technical reports and publications to her credit  dr chawla also serves on the board of trustees of newbury college in brookline massachusetts  she has served as a reviewer or referee for several journals including value in health health affairs health services research journal of the american medical association and journal of business and economic statistics  dr chawla holds a phd in economics from the university of michigan and received a bachelor of arts degree in economics and political science from wellesley collegedr anita chawla bears no familial relation to sant p chawla md fracp director of the sarcoma oncology center and principal investigator of the companys global phase  clinical trial in soft tissue sarcoma or shanta chawla md vice president clinical development at cytrxabout cytrx corporationcytrx corporation is a biopharmaceutical research and development company specializing in oncology  cytrx currently is focused on the clinical development of aldoxorubicin formerly known as inno its improved version of the widely used chemotherapeutic agent doxorubicin cytrx has initiated under a special protocol assessment a pivotal phase  global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy and recently announced that it has received approval from the fda to continue dosing patients with aldoxorubicin until disease progression in that clinical trial cytrx is currently evaluating aldoxorubicin in a global phase b clinical trial in small cell lung cancer a phase  clinical trial in hivrelated kaposis sarcoma a phase  clinical trial in patients with latestage glioblastoma brain cancer a phase b trial in combination with ifosfamide in patients with soft tissue sarcoma and a phase b trial in combination with gemcitabine in subjects with metastatic solid tumors cytrx has completed a global phase b clinical trial with aldoxorubicin as a firstline therapy for soft tissue sarcomas a phase b clinical trial primarily in the same indication a phase b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a phase b pharmacokinetics clinical trial in patients with metastatic solid tumors cytrx plans to expand its pipeline of oncology candidates at its laboratory facilities in freiburg germany based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites  for more information about cytrx corporation visit wwwcytrxcom  forwardlooking statementsthis press release contains forwardlooking statements within the meaning of section e of the securities exchange act of  as amended such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forwardlooking statements including risks relating to the outcome timing and results of cytrxs clinical trials the timing or fda approval of projected commercial sales of aldoxorubicin the risk that any future human testing of aldoxorubicin might not produce results similar to those seen in past human or animal testing risks related to cytrxs ability to manufacture its drug candidates in a timely fashion costeffectively or in commercial quantities in compliance with stringent regulatory requirements risks related to cytrxs need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts including the phase  clinical development of aldoxorubicin risks related to lawsuits that have been brought against the company and its officers andor directors for alleged violations of the securities laws and the risks and uncertainties described in the most recent annual and quarterly reports filed by cytrx with the securities and exchange commission and current reports filed since the date of cytrxs most recent annual report all forwardlooking statements are based upon information available to cytrx on the date the statements are first published cytrx undertakes no obligation to publicly update or revise any forwardlooking statements whether as a result of new information future events or otherwiseinvestor relations argot partners michelle carroll michelleargotpartnerscommedia argot partners eliza schleifstein elizaargotpartnerscomcompany contact cytrx corporation david j haenvice president business development and investor relations  x dhaencytrxcom  to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesdranitajchawlajoinscytrxboardofdirectorstoaddadditionaldrugcommercializationexpertiseinoncologyhtmlsource cytrx corporation help employers find you check out all the jobs and post your resume read at biospacecom related news cytrx corporation cytr reports  financial results netscientific appoints jonathan paisner as nonexecutive director cytrx corporation cytrs brain cancer drug shows promise in midstage study at a top notch facility in socal amgen amgn works on perfecting and cranking out biosimilars cytrx corporation cytr announces overall survival results from its global phase b clinical trial of aldoxorubicin in soft tissue sarcoma astrazeneca plc azn ceo rewarded with  pay raise after fending off pfizer pfe fda removes partial clinical hold on cytrx corporation cytrs brain cancer trials blood samples as surrogates for tumor biopsies in patients with lung cancer yale university school of medicine study cytrx corporation cytr announces positive interim phase  aldoxorubicin results as a treatment for hivrelated kaposis sarcoma ks new breast cancer test can predict survival chances  institute of clinical research study please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • cytrx corporation   • biotechpharma  personnel • clinical  phase i • clinical  phase iii • clinical  phase ii   • cancer misc               cytrx appoints anita chawla to the board of directors email protected twitterlinkedin about our vision our mission our team our values our partners faq terms  conditions privacy policy board news latest board news board news by location… europe usa  canada middle east all the others board news by company type public  listed vc  pe backed privately held trust  fund  reit board news by industry… life sciences  health care financials information technology women on board submit a press release board directory company press releases public  listed global  fortune  private or vc  pe backed unicorns trust  fund newsletter contact log in register select pageabout    our vision our mission     our team     our values     our partners     faq     terms  conditions     privacy policy board news    latest board news     board news by location…        europe         usa  canada         middle east         all the others     board news by company type        public  listed         vc  pe backed         privately held         trust  fund  reit     board news by industry…        life sciences  health care         financials         information technology     women on board     submit a press release board directory    company press releases     public  listed     global      fortune      private or vc  pe backed     unicorns     trust  fund newsletter contact log in register homeboard  usa  can board listedpublic companies diversity on board cytrx appoints anita chawla to the board of directors cytrx appoints anita chawla to the board of directors march   by talentboards team comments are off board  usa  can board listedpublic companies diversity on board – usa ca – cytrx corporation nasdaqcytr a biopharmaceutical research and development company specializing in oncology today announced the appointment of anita j chawla phd to its board of directors dr chawla brings over  years of experience as an economist in the health care industry to cytrx with a proven track record helping pharmaceutical biotechnology medical device and diagnostic companies achieve their product development and commercialization objectives most recently she has provided strategic consultancy services to a variety of life science companies including cytrx with broad experience advising companies in matters including corporate and business unit strategy market dynamics across multiple therapeutic areas reimbursement health economics and business analytics her appointment strengthens the executive leadership team and adds significant operational and commercial expertise “we are delighted to welcome anita to the cytrx board of directors” said steven a kriegsman chairman and ceo of cytrx “anita is a talented health economist who has become a very successful and trusted advisor to biopharmaceutical companies she has been intimately involved in providing strategic guidance for product development and commercialization in oncology for many successful biopharmaceutical companies and we believe her contributions will be invaluable as we prepare to commercialize aldoxorubicin and other new treatments for cancer patients” “cytrx’s aldoxorubicin is a novel targeted therapeutic that has shown promise in various oncology clinical trials and has significant potential in several cancer types” said dr chawla “i look forward to working alongside the board and management team to help cytrx navigate the clinical and commercial development of its lead asset and create long term value for shareholders” dr chawla currently serves as managing principal at analysis group a consultancy firm that provides economic financial and business strategy consulting to corporations law firms and government agencies clients include major pharmaceutical manufacturers biotech and medical device companies including smaller innovative companies prior to joining analysis group she held positions at genentech inc as the head of the health economics  outcomes research department where she also supported the oncology franchise the medstat group now truven health analytics and the american medical association center for health policy research she has over  professional presentations technical reports and publications to her credit dr chawla also serves on the board of trustees of newbury college in brookline massachusetts she has served as a reviewer or referee for several journals including value in health health affairs health services research journal of the american medical association and journal of business and economic statistics dr chawla holds a phd in economics from the university of michigan and received a bachelor of arts degree in economics and political science from wellesley college dr anita chawla bears no familial relation to sant p chawla md fracp director of the sarcoma oncology center and principal investigator of the company’s global phase  clinical trial in soft tissue sarcoma or shanta chawla md vice president clinical development at cytrx about cytrx corporation cytrx corporation is a biopharmaceutical research and development company specializing in oncology cytrx currently is focused on the clinical development of aldoxorubicin formerly known as inno its improved version of the widely used chemotherapeutic agent doxorubicin cytrx has initiated under a special protocol assessment a pivotal phase  global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy and recently announced that it has received approval from the fda to continue dosing patients with aldoxorubicin until disease progression in that clinical trial cytrx is currently evaluating aldoxorubicin in a global phase b clinical trial in small cell lung cancer a phase  clinical trial in hivrelated kaposi’s sarcoma a phase  clinical trial in patients with latestage glioblastoma brain cancer a phase b trial in combination with ifosfamide in patients with soft tissue sarcoma and a phase b trial in combination with gemcitabine in subjects with metastatic solid tumors cytrx has completed a global phase b clinical trial with aldoxorubicin as a firstline therapy for soft tissue sarcomas a phase b clinical trial primarily in the same indication a phase b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a phase b pharmacokinetics clinical trial in patients with metastatic solid tumors cytrx plans to expand its pipeline of oncology candidates at its laboratory facilities in freiburg germany based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites  disclaimer  news data and statement included in this release are intended exclusively for information purposes product and brand names used in this release maybe trademarks or registered trade marks of their respective owners talentboards accepts neither liability for the consequences of the reader’s reliance nor responsibility for the adequacy or accuracy of this release no data or statement in this release should be considered a recommendation for the purchase retention or sale of the securities referred to hereinother related postscytrx appoints cheryl cohen to its board of directorscarmax appoints sona chawla to its board of directorsnemucore medical innovations adds dr michael seiden to its board of directorstalentboards teamhere the original post  comments are closed latest boardroom news relx group announces suzanne wood as upcoming nonexecutive director of relx nv relx plc and relx group plc july   columbia banking system appointed randy lund to its board of directors july   union pacific appoints bob patel to its board of directors july   new gold adds marilyn schonberner to its board of directors along with new appointments in the senior management members july   oil states international welcomes bob potter to its board of directors july   random boardscell medicachoice hotels international omeicos therapeuticseurazeocic gold    talentboards inc  all rights reserved  geneva  miami  london  boston  paris  shanghai  monaco  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip